Patents by Inventor Chang-Gong Liu

Chang-Gong Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170175123
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Application
    Filed: August 15, 2016
    Publication date: June 22, 2017
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Patent number: 9506065
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: November 29, 2016
    Assignee: Thomas Jefferson University
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Publication number: 20150368647
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Application
    Filed: September 4, 2015
    Publication date: December 24, 2015
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Patent number: 9150859
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: October 6, 2015
    Assignee: Thomas Jefferson University
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Publication number: 20140256040
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Application
    Filed: May 19, 2014
    Publication date: September 11, 2014
    Applicant: Thomas Jefferson University
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Patent number: 8778676
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: July 15, 2014
    Assignee: Thomas Jefferson University
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Publication number: 20130330403
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 12, 2013
    Applicant: Thomas Jefferson University
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Publication number: 20100234241
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Application
    Filed: April 26, 2010
    Publication date: September 16, 2010
    Applicant: Thomas Jefferson University
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Publication number: 20100203544
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Application
    Filed: March 31, 2010
    Publication date: August 12, 2010
    Applicant: Thomas Jefferson University
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Patent number: 7723030
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: May 25, 2010
    Assignee: Thomas Jefferson University
    Inventors: Carlo M. Croce, Chang-Gong Liu, George A. Calin, Cinzia Sevignani
  • Publication number: 20060105360
    Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.
    Type: Application
    Filed: July 29, 2005
    Publication date: May 18, 2006
    Inventors: Carlo Croce, Chang-Gong Liu, George Calin, Cinzia Sevignani
  • Patent number: 6986992
    Abstract: This invention relates to methods and compositions for determining single nucleotide polymorphisms (SNPs) in P450 genes. In preferred embodiments, self extension of interrogation probes is prevented by using novel non self-extension probes and/or methods, thereby improving the specificity and efficiency of P450 SNP detection in target samples with minimal false positive results. The invention thus describes a variety of methods to decrease self-extension of interrogation probes. In addition, this invention provides a unique collection of P450 SNP probes on one assay, primer sequences for specific amplification of each of the seven P450 genes and amplicon control probes to evaluate whether the intended p450 gene targets were amplified successfully. The invention also describes a variety of array platforms for performing the assays of the invention; for example: CodeLinkā„¢, eSensorā„¢, multiplex arrays with cartridges etc., all described herein.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: January 17, 2006
    Assignee: Amersham Biosciences AB
    Inventors: Buena Chui, Robert Elghanian, Vineet Gupta, Krishnamurthy Jayaraman, Gretchen Kiser, Changming Li, Chang-Gong Liu, Kenneth R. Luehrsen, Abhijit Mazumder, Ramesh Ramakrishnan, Arkadiy Silbergleyt, Todd Tuggle, Carl Yamashiro, Handy Yowanto, Ekaterina Pestova, David R. Fermin, David G. Wang, Zhijie John Gu
  • Patent number: 6921638
    Abstract: Methods and devices for detecting nucleic acid and protein targets on hydrogel microarrays are disclosed. Fluorophores are incorporated into the targets and detected. A linear correlation between target concentration and signal amplitude is maintained through the elimination of active enzyme amplification.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: July 26, 2005
    Assignee: Amersham Biosciences AB
    Inventors: Chang-Gong Liu, Abhijit Mazumder, Charles K. Brush, W. Travis Johnson
  • Publication number: 20040229222
    Abstract: This invention relates to methods and compositions for determining single nucleotide polymorphisms (SNPs) in P450 genes. In preferred embodiments, self extension of interrogation probes is prevented by using novel non self-extension probes and/or methods, thereby improving the specificity and efficiency of P450 SNP detection in target samples with minimal false positive results. The invention thus describes a variety of methods to decrease self-extension of interrogation probes. In addition, this invention provides a unique collection of P450 SNP probes on one assay, primer sequences for specific amplification of each of the seven P450 genes and amplicon control probes to evaluate whether the intended p450 gene targets were amplified successfully. The invention also describes a variety of array platforms for performing the assays of the invention; for example: CodeLink™, eSensor™, multiplex arrays with cartridges etc., all described herein.
    Type: Application
    Filed: April 1, 2002
    Publication date: November 18, 2004
    Inventors: Buena Chui, Robert Elghanian, Vineet Gupta, Krishnamurthy Jayaraman, Gretchen Kiser, Changming Li, Chang-Gong Liu, Kenneth R. Luehrsen, Abhijit Mazumder, Ramesh Ramakrishnan, Arkadiy Silbergleyt, Todd Tuggle, Carl Yamashiro, Handy Yowanto, Ekaterina Pestova, David R. Fermin, David G. Wang, Zhijie John Gu
  • Publication number: 20020146730
    Abstract: Methods and devices for detecting nucleic acid and protein targets on hydrogel microarrays are disclosed. Fluorophores are incorporated into the targets and detected. A linear correlation between target concentration and signal amplitude is maintained through the elimination of active enzyme amplification.
    Type: Application
    Filed: December 19, 2001
    Publication date: October 10, 2002
    Inventors: Chang-Gong Liu, Abhijit Mazumder, Charles K. Brush, W. Travis Johnson